Substituted 2-pyrimidineamines and processes for their preparation
AssigneeCelltech Therapeutics Limited
InventorsPeter David Davis, David Festus Charles Moffat, Mark James Batchelor
Life of this patent
Estimating the term…
Loading patent…
AssigneeCelltech Therapeutics Limited
InventorsPeter David Davis, David Festus Charles Moffat, Mark James Batchelor
Estimating the term…
Compounds of general formula (1): ##STR1## are described wherein Het is an optionally substituted heteroaromatic group; R.sup.1 is a hydrogen atom or a straight or branched chain alkyl group; R.sup.2 is a hydrogen or halogen atom or a group --X.sup.1 --R.sup.2a where X.sup.1 is a direct bond or a linker atom or group, and R.sup.2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R.sup.3 is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein kinase inhibitors, particularly the kinases p56.sup.lck, ZAP-70 and protein kinase C and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.
A compound which is selected from the group consisting of:
Dependencies are inferred from the claim text.